AI Article Synopsis

  • CHARGE syndrome is a rare genetic disorder caused by mutations in a specific gene and is usually inherited in an autosomal dominant manner.
  • A specific mutation (c.7165-4A>G) was found in a Japanese boy diagnosed with CHARGE syndrome, but it's categorized as an "unclassified variant" because it doesn't occur at the typical splicing sites.
  • Researchers validated the abnormal splicing resulting from this variant using cDNA sequencing, confirming its impact on the disorder.

Article Abstract

CHARGE syndrome is a rare autosomal dominant disease that is typically caused by heterozygous mutations. A variant in a splicing acceptor site (NM_017780.3:c.7165-4A>G) was identified in a Japanese boy with CHARGE syndrome. This variant has been considered to be an "unclassified variant" due to its position outside the consensus splicing sites. In this study, abnormal splicing derived from this known variant was confirmed by cDNA sequencing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842149PMC
http://dx.doi.org/10.1038/hgv.2018.6DOI Listing

Publication Analysis

Top Keywords

charge syndrome
12
unclassified variant
4
variant activates
4
activates cryptic
4
cryptic splice
4
splice site
4
site patient
4
patient charge
4
syndrome charge
4
syndrome rare
4

Similar Publications

Applications of mass spectrometry imaging in botanical research.

Adv Biotechnol (Singap)

February 2024

State Key Laboratory of Traditional Chinese Medicine/School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.

Mass spectrometry imaging (MSI) serves as a valuable tool enabling researchers to scrutinize various compounds, peptides, and proteins within a sample, providing detailed insights at both elemental and molecular levels. This innovative technology transforms information obtained from a mass spectrometer- encompassing ionic strength, mass-to-charge ratio, and ionized molecule coordinates-within a defined region into a pixel-based model. Consequently, it reconstructs the spatial distribution of ions, allowing for a comprehensive understanding of molecular landscapes.

View Article and Find Full Text PDF

Prevention of refeeding syndrome: Evaluation of an enteral refeeding protocol for severely undernourished children.

J Pediatr Gastroenterol Nutr

January 2025

Hospices Civil de Lyon, Hôpital Femme Mère Enfant, Service de Gastroentérologie, Hépatologie et Nutrition Pédiatriques, Université Claude Bernard Lyon-1, CarMeN Laboratory, INRAE, UMR1397, INSERM, UMR1060, Pierre-Bénite, France.

Objectives: Refeeding syndrome (RS) defines the deleterious clinical and metabolic changes occurring during nutritional support of severely malnourished patients. Pediatric guidelines to prevent and treat RS are scarce and highly variable. This study aimed to evaluate the effectiveness and safety of an enteral refeeding protocol in severely undernourished hospitalized children with anorexia nervosa (AN) or organic diseases (OD).

View Article and Find Full Text PDF

Background:  COVID-19 is known to cause significant multisystem inflammatory responses, leading to symptoms beyond the acute phase of illness. These "long COVID" symptoms affect quality of life and interfere with daily activities. This pilot study looks at the feasibility, tolerability, and safety of omega-3 (docosahexaenoic acid+eicosapentaenoic acid, EPA) among healthcare workers with long COVID symptoms in New Jersey.

View Article and Find Full Text PDF

Objectives: This study aimed to assess the role of olfactory sulci (OS) in diagnosing CHARGE syndrome among fetuses with major congenital heart defects (CHDs).

Methods: We prospectively evaluated OS development in fetuses diagnosed with CHDs from 2017 to 2021. Neurosonography (NSG) was performed using transabdominal and transvaginal approaches after 30 weeks of gestation.

View Article and Find Full Text PDF

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly arrhythmogenic syndrome triggered by stress, primarily linked to gain-of-function point mutations in the cardiac ryanodine receptor (RyR2). Flecainide, as an effective therapy for CPVT, is a known blocker of the surface-membrane Na channel, also affecting the intracellular RyR2 channel. The therapeutic relevance of the flecainide-RyR2 interaction remains controversial, as flecainide blocks only the RyR2 current flowing in the opposite direction to the physiological Ca release from the sarcoplasmic reticulum (SR).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!